Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists

• Päätekijät: Alessandro Boianelli (Tekijä), Pär Nordell (Tekijä), Joseph Earl (Tekijä), Jacqueline Naylor (Tekijä), David Hornigold (Tekijä), Rasmus Jansson Löfmark (Tekijä), Monika Sundqvist (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2024-10-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.
• Notes: 10.3390/pharmaceutics16101310; 1999-4923
• Keywords: GLP-1 agonists; in vitro in vivo correlation; PK/PD modelling; model informed drug development (MIDD); Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 16, Iss 10, p 1310 (2024)

<b>Background:</b> Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play an important role in the treatment of type 2 diabetes (T2D) and obesity. The relationship between efficacy and dosing regimen has been studied extensively for this class of molecules. However, a comprehensive analysis of the translation of in vitro data to in vivo efficacious exposure is still lacking. <b>Methods:</b> We collected clinical pharmacokinetics for five approved GLP-1RAs to enable the simulation of exposure profiles and compared published clinical efficacy endpoints (HbA1c and body weight) with in-house in vitro potency values generated in different cell-based assays. Additionally, we investigated the correlation with target coverage, expressed as a ratio between the steady state drug exposure and unbound potency, body weight, or HbA1c reduction in patients with T2D. <b>Results:</b> We found that the best correlation with in vivo efficacy was seen for in vitro potency data generated in cellular assays performed in the absence of any serum albumin or using ovalbumin. Residual variability was larger using in vitro potency data generated in endogenous cell lines or in the presence of human serum albumin. For the human receptor assay with no albumin, exposures above 100-fold in vitro EC50 resulted in >1.5% point HbA1c reduction, while a 5% BW reduction was related to approximately 3× higher exposures. A similar relationship was seen in the ovalbumin assay. <b>Conclusions:</b> Overall, the relationship established for in vitro potency and in vivo efficacy will help to increase confidence in human dose prediction and trial design for new GLP-1RAs in the discovery and early clinical phases.